Revvity is trying to prove that the leftover PerkinElmer franchise can compound as a cleaner diagnostics and life-science tools company once the China immunodiagnostics drag is sold. The July quarter showed Diagnostics doing the heavy lifting while Life Sciences still shrank organically, and management signed a definitive sale of the China unit and raised the full-year organic outlook. The investment debate is whether that mix is a durable reset or a one-quarter bounce dressed up by a tariff refund and a software comparison that is about to get easier. Chief executive Prahlad Singh described demand as returning across the customer base. The equity has already moved as if that return is durable.
The earnings beat is real and also messy. Diagnostics grew at a double-digit organic clip once China is stripped out, which is the franchise the company wants investors to underwrite. Life Sciences still contracted, and the Signals software line dropped hard on a tough comparison and contract timing. A tariff refund of sixteen million padded both margin and adjusted earnings by about eleven cents a share. Strip that refund and the operating story is still better than the weak first quarter, but it is not as clean as the headline implies. Cash conversion stayed strong, which is the part of the print that does not depend on a refund.
The next two quarters resolve whether the instrument backlog converts, whether Signals software returns to growth, and whether Diagnostics can keep growing without the China unit. Management lifted pro forma organic growth into a mid-single-digit band and nudged adjusted earnings higher. Shares closed at $143 on the publication date, near the top of the fifty-two week range after a sharp mid-September run. The price already assumes the second-half recovery shows up.